6-[[[2-[[2-(2S)-2-氰基-1-吡咯烷基]-2-氧乙基]氨基]乙基]氨基-3-吡啶碳腈二盐酸盐 | 207556-62-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 6-[[[2-[[2-(2S)-2-氰基-1-吡咯烷基]-2-氧乙基]氨基]乙基]氨基-3-吡啶碳腈二盐酸盐
• 英文名称: Nvp dpp 728 dihydrochloride
• 英文别名: 6-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride
• CAS: 207556-62-5
• 化学式: C15H20Cl2N6O
• 分子量: 371.3
• InChiKey: VNACOBVZDCLAEV-GXKRWWSZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  105
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] INDOLYLMALEIMIDE DERIVATIVES<br/>[FR] DERIVES D'INDOLYLMALEIMIDE
  申请人：NOVARTIS AG

  公开号：WO2005068454A1

  公开（公告）日：2005-07-28

  A compound of formula I wherein R, Re, Rb, Rc, Rd and Re are as defined in the, specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

  式I的化合物，其中R、Re、Rb、Rc、Rd和Re如规范中定义的那样，它们的生产方法，它们的用途，特别是在移植中，以及含有它们的药物组合物。
• [EN] INDOLYLMALEIMIDE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLYLMALÉIMIDE
  申请人：NOVARTIS AG

  公开号：WO2003082859A1

  公开（公告）日：2003-10-09

  Provided are compounds of Formula (I), which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infraction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of (I) are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto’s thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren’s syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn’s disease or ulcerative colitis.

  提供的是化合物的化学式（I），可用于治疗和/或预防由T淋巴细胞和/或PKC介导的疾病或紊乱，例如器官或组织同种异体或异种移植的急性或慢性排斥、移植物抗宿主病、动脉粥样硬化、由血管损伤引起的血管闭塞，如血管成形术后的再狭窄、肥胖、X综合征、糖耐量受损、多囊卵巢综合征、高血压、心力衰竭、慢性阻塞性肺疾病、中枢神经系统疾病，如阿尔茨海默病或肌萎缩侧索硬化、癌症、感染性疾病，如艾滋病、脓毒性休克或成人呼吸窘迫综合征、缺血/再灌注损伤，例如心肌梗死、中风、肠道缺血、肾功能衰竭或出血性休克，或创伤性休克，例如创伤性脑损伤。化合物（I）也可用于治疗和/或预防T细胞介导的急性或慢性炎症性疾病或紊乱或自身免疫性疾病，例如类风湿性关节炎、骨关节炎、系统性红斑狼疮、Hashimoto甲状腺炎、多发性硬化症、重症肌无力、糖尿病I型或II型及相关疾病，例如血管病、糖尿病性增生性视网膜病变、糖尿病性黄斑水肿、肾病、神经病和晨间现象、呼吸系统疾病，如哮喘或炎症性肺损伤、炎症性肝损伤、炎症性肾小球损伤、免疫介导疾病或疾病的皮肤表现、炎症性和过度增生性皮肤疾病（如银屑病、特应性皮炎、过敏性接触性皮炎、刺激性接触性皮炎和其他湿疹性皮炎、脂溢性皮炎）、炎症性眼部疾病，如干燥综合征、角膜结膜炎或葡萄膜炎、炎症性肠疾病、克罗恩病或溃疡性结肠炎。
• Cyanopyrrolidine derivatives
  申请人：——

  公开号：US20040072892A1

  公开（公告）日：2004-04-15

  A cyanopyrrolidine derivative represented by Formula (1): 1 [wherein R 1 is a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, R 2 is a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 1 and R 2 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, R 3 and R 4 are each a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 3 and R 4 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, X is an oxygen atom or a sulfur atom, Y is —CR 5 R 6 — (wherein R 5 and R 6 are the same or different, and are each a hydrogen atom, a halogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms or an optionally substituted alkenyl group having 2 to 10 carbon atoms), or —CR 7 R 8 —CR 9 R 10 — (wherein R 7 , R 8 , R 9 and R 10 are the same or different, and each a hydrogen atom, a halogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or R 7 and R 9 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl group having 3 to 8 carbon atoms, an optionally substituted cycloalkenyl group having 4 to 8 carbon atoms, an optionally substituted bicycloalkyl group having 5 to 10 carbon atoms, or an optionally substituted bicycloalkenyl group having 5 to 10 carbon atoms) and Z is a hydrogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or Y and Z together with the nitrogen atom to which they are attached form an optionally substituted cyclic amino group having 2 to 10 carbon atoms], or a pharmaceutically acceptable salt thereof.

  一种由式（1）表示的氰基吡咯烷衍生物：1［其中R1是卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，R2是氢原子，卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，或R1和R2一起形成氧代，羟肟基，具有1至5个碳原子的烷氧肟基或具有1至5个碳原子的烷基亚甲基，R3和R4分别是氢原子，卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，或R3和R4一起形成氧代，羟肟基，具有1至5个碳原子的烷氧肟基或具有1至5个碳原子的烷基亚甲基，X是氧原子或硫原子，Y是- CR5R6-（其中R5和R6相同或不同，且均为氢原子，卤素原子，具有1至10个碳原子的可选取代烷基或具有2至10个碳原子的可选取代烯基），或-CR7R8-CR9R10-（其中R7，R8，R9和R10相同或不同，且均为氢原子，卤素原子或具有1至10个碳原子的可选取代烷基，或R7和R9与它们附着的碳原子一起形成具有3至8个碳原子的可选取代环烷基，具有4至8个碳原子的可选取代环烯基，具有5至10个碳原子的可选取代双环烷基或具有5至10个碳原子的可选取代双环烯基），Z是氢原子或具有1至10个碳原子的可选取代烷基，或Y和Z与它们附着的氮原子一起形成具有2至10个碳原子的可选取代环氨基，或其药学上可接受的盐。
• Indolylmaleimide derivatives
  申请人：Evenou Jean-Pierre

  公开号：US20050119274A1

  公开（公告）日：2005-06-02

  Provided are compounds of formula (I) which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory disease or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contract dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.

  提供的化合物式(I)可用于治疗和/或预防由T淋巴细胞和/或PKC介导的疾病或疾病，例如器官或组织同种或异种移植的急性或慢性排斥反应，移植物抗宿主病，动脉粥样硬化，由于血管损伤如血管成形术而导致的血管闭塞，再狭窄，肥胖，综合征X，糖耐量受损，多囊卵巢综合症，高血压，心力衰竭，慢性阻塞性肺疾病，中枢神经系统疾病，例如阿尔茨海默病或肌萎缩侧索硬化，癌症，传染病，例如艾滋病，脓毒症或成人呼吸窘迫综合征，缺血/再灌注损伤，例如心肌梗塞，中风，肠道缺血，肾衰竭或出血性休克，或创伤性休克，例如创伤性脑损伤。公式I的化合物也可用于治疗和/或预防T细胞介导的急性或慢性炎症性疾病或疾病或自身免疫性疾病，例如类风湿性关节炎，骨关节炎，系统性红斑狼疮，桥本甲状腺炎，多发性硬化症，重症肌无力，糖尿病I型或II型及其相关疾病，例如血管病，糖尿病增生性视网膜病变，糖尿病黄斑水肿，肾病，神经病和黎明现象，呼吸道疾病，例如哮喘或炎性肺损伤，炎性肝损伤，炎性肾小球损伤，免疫介导疾病或疾病的皮肤表现，炎症和过度增生性皮肤疾病（例如银屑病，特应性皮炎，过敏性接触性皮炎，刺激性接触性皮炎和进一步的湿疹性皮炎，脂溢性皮炎），炎症性眼疾，例如干燥综合征，角膜结膜炎或葡萄膜炎，炎症性肠病，克隆氏病或溃疡性结肠炎。
• Indolylmaleimide Derivatives
  申请人：Wagner Jurgen

  公开号：US20080318975A1

  公开（公告）日：2008-12-25

  A compound of formula (I) wherein R, R 1 , and R 2 , ring A and ring B are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

  一种化合物的公式(I)，其中R，R1和R2，环A和环B如规范所定义，它们的制备过程，它们的用途，特别是在移植中使用，并且包含它们的制药组合物。